{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:55:38Z","timestamp":1781639738768,"version":"3.54.5"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To discuss the recent evidence that Janus kinase (JAK) inhibitors can cause viral retinitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A commentary on the case report in this issue and a review of cases in the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 6 cases have now been reported of cytomegalovirus retinitis associated with Jak inhibitors. Additionally, there was a case of bilateral toxoplasma retinitis and a case of herpetic scleritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>It is important to be aware of the potential blinding complications associated with JAK inhibitors and if the patient complains of acute vision loss and\/or floaters, the patient should be emergently referred to a retina specialist.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00823-4","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:00:07Z","timestamp":1772791207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Infectious retinitis associated with JAK inhibitors: the ongoing duality of JAK inhibitors"],"prefix":"10.1186","volume":"12","author":[{"given":"Jose S.","family":"Pulido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fukutaro","family":"Mano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Casella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"823_CR1","doi-asserted-by":"crossref","unstructured":"Watanabe D, Namba K, Hase K, Suzuki K, Ogino Y, Saito M, et al. Acute retinal necrosis during the systemic use of Janus kinase inhibitor. Int J Retina Vitreous. 2026.","DOI":"10.1186\/s40942-025-00756-4"},{"issue":"5","key":"823_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/ICB.0000000000001626","volume":"19","author":"MJ Smith","year":"2025","unstructured":"Smith MJ, Lim JI, Chau FY, Lobo-Chan AM. Cytomegalovirus Retinitis in Non-HIV Immunocompromised Individuals on Tofacitinib for Rheumatoid Arthritis. Retinal Cases Brief Rep. 2025;19(5):603\u20137.","journal-title":"Retinal Cases Brief Rep"},{"key":"823_CR3","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1093\/rheumatology\/kez681","volume":"59","author":"DR Cugley","year":"2020","unstructured":"Cugley DR, Darby J, Lim LL. Tofacitinib-associated cytomegalovirus retinitis. Rheumatology (Oxford). 2020;59:e35\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"823_CR4","first-page":"e48337","volume":"15","author":"H Hirai","year":"2023","unstructured":"Hirai H, Akai Y, Ogata N, Ueda T. Cytomegalovirus Retinitis in a Patient Taking Upadacitinib: A Case Report. Cureus. 2023;15:e48337.","journal-title":"Cureus"},{"key":"823_CR5","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jiac.2017.03.002","volume":"23","author":"K Yanagisawa","year":"2017","unstructured":"Yanagisawa K, Ogawa Y, Hosogai M, Todokoro D, Mitsui T, Yokohama A, et al. Cytomegalovirus retinitis followed by immune recovery uveitis in an elderly patient with rheumatoid arthritis undergoing administration of methotrexate and tofacitinib combination therapy. J Infect Chemother. 2017;23:572\u20135.","journal-title":"J Infect Chemother"},{"key":"823_CR6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJMc1413918","volume":"374","author":"J von Hofsten","year":"2016","unstructured":"von Hofsten J, Johnsson Forsberg M, Zetterberg M. Cytomegalovirus Retinitis in a Patient Who Received Ruxolitinib. N Engl J Med. 2016;374:296\u20137.","journal-title":"N Engl J Med"},{"key":"823_CR7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1056\/NEJMc1302895","volume":"369","author":"RA Goldberg","year":"2013","unstructured":"Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med. 2013;369:681\u20133.","journal-title":"N Engl J Med"},{"key":"823_CR8","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1080\/09273948.2022.2113805","volume":"32","author":"R Pyare","year":"2024","unstructured":"Pyare R, Dutta MP, Shah M, Kaushik V, Agarwal M, Biswas J. Tofacitinib in Scleritis: A Case Series. Ocul Immunol Inflamm. 2024;32:884\u201390.","journal-title":"Ocul Immunol Inflamm"},{"key":"823_CR9","unstructured":"The Janus Kinase Inhibitor Global Market Report. 2025. https:\/\/www.thebusinessresearchcompany.com\/report\/janus-kinase-jak-inhibitors-global-market-report. Accessed 29 Nov 2025."},{"key":"823_CR10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamaophthalmol.2024.2439","volume":"142","author":"SK Srivastava","year":"2024","unstructured":"Srivastava SK, Watkins TR, Nguyen QD, Sharma S, Scales DK, Dacey MS, et al. Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial. JAMA Ophthalmol. 2024;142:789\u201397.","journal-title":"JAMA Ophthalmol"},{"key":"823_CR11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40264-025-01535-8","volume":"48","author":"R Di Napoli","year":"2025","unstructured":"Di Napoli R, Richez C, Scavone C, Singier A, Demourgues M, Mascolo A, et al. Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database. Drug Saf. 2025;48:943\u201352.","journal-title":"Drug Saf"},{"key":"823_CR12","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","volume":"12","author":"L Hoisnard","year":"2022","unstructured":"Hoisnard L, Lebrun-Vignes B, Maury S, Mahevas M, El Karoui K, Roy L, et al. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022;12:7140.","journal-title":"Sci Rep"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00823-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00823-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00823-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:29:32Z","timestamp":1781638172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00823-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["823"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00823-4","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"29 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}